Oncology

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

The medication’s ability to reduce inflammation sited as one possible explanation.

Study highlights the need for services and research for this understudied population.

Study shows Clovis Oncology’s rucaparib shows clinically meaningful impact in delaying disease recurrence in ovarian cancer.

Understanding genetic variations and tumor differences in black women with breast cancer could lead to personalized diagnosis and treatment.

New research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.

Alcohol consumption is known to be a risk factor for breast cancer based on studies predominantly done in white women. Now, a University of North Carolina Lineberger Comprehensive Cancer Center study has found the same risk exists for black women.

A new study provides new insights into the epidemiology of breast cancer among the most prominent Asian-American ethnic groups in California.

New findings reveal this genetic test to assess breast cancer risk could be more effective than others.

Oncology is a complex and rapidly-evolving management challenge for payers.

Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.

There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.

An ASH presenter describes how better health IT and better institutional practices are necessary to leverage EHRs for quality of care.

Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.

Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.

The Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.

HHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.

De-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?

Most patients hear the word “carcinoma” or “cancer” and believe they may die if they do not seek treatment. But ASCO researchers say that may be a problematic mentality.

Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?

Targeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.

Patient-reported outcomes are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development-and even routine clinical cancer care.

A look at how burnout affects providers, their patients, and the centers that employ them.

Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.

ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies